Title

Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules
Evaluation of the Efficacy of a Supplement With Spirulina for Amelioration of Benign Thyroid Nodules
  • Phase

    N/A
  • Study Type

    Interventional
  • Intervention/Treatment

    spirulina ...
  • Study Participants

    38
Clinical trial with a double-blind, placebo-controlled, crossover design; enrolls approximately 30 euthyroid patients with benign thyroid nodules, who will receive for 6 weeks a spirulina-based supplement, and for another 6 weeks placebo. Thyroid ecography will be performed three times for each patient, and blood tests including TSH, free T4, free T3 and ceruloplasmin/Copper will also be performed 3 times for each patient. It is expected that a decrease in the thyroid nodules occurs with the supplement administration. Compared with placebo there will be a decrease of at least 20% in the volume or the largest diameter of the nodules during the 6-week administration of the supplement.
Clinical trial with double-blind, placebo-controlled, crossover design; enrolls approximately 30 euthyroid patients with benign thyroid nodules, who will receive for 6 weeks a spirulina-based supplement, and for another 6 weeks placebo.

The sequence of administration supplement - placebo is unknown to the doctor or the patients
The supplement and placebo are placed in identical capsules and vials by DVR Pharm
The respective capsules are administered twice a day Thyroid ecography will be performed three times for each patient, and blood tests including TSH, free T4, free T3 and ceruloplasmin/Copper will also be performed 3 times for each patient.
Echography and blood tests will be performed for each patient initially, after 6 weeks, and after 12 weeks It is expected that a decrease in the thyroid nodules occurs with the supplement administration.
there will be a direct comparison of the nodules dimensions on the ecographic examinations, in millimeters, and of the blood levels of the molecules which reflect thyroid function
Study Started
May 15
2018
Primary Completion
Dec 20
2018
Study Completion
Dec 21
2018
Results Posted
May 19
2020
Last Update
May 19
2020

Dietary Supplement Preparation with Spirulina

Preparation with Spirulina to ameliorate the size of benign thyroid nodules

Dietary Supplement Placebo

Placebo administration for 6 weeks bid

Preparation with Spirulina Active Comparator

6 weeks bid Preparation with Spirulina

Placebo Placebo Comparator

6 weeks bid Placebo

Criteria

Inclusion Criteria:

euthyroid adults (normal TSH)
no criteria for malignancy is present (size, fine needle aspiration, lymph nodules)
no other medication/supplement administered for thyroid, no steroids, beta-blocker

Exclusion Criteria:

suspicion of malignancy / shown
autoimmune disease
abnormal thyroid function
Wilson disease
contraception with intrauterine device

Summary

Preparation With Spirulina

Placebo

All Events

Event Type Organ System Event Term Preparation With Spirulina Placebo

Percent Change in Area of Thyroid Nodules

Size of the thyroid nodules is measured by ultrasound, two perpendicular diameters, same incidence and operator at V1 and V2 Area of nodules is calculated as the product of the two diameters

Preparation With Spirulina

-19.98
percentage change (Mean)
Standard Deviation: 15.55

Placebo

-9.31
percentage change (Mean)
Standard Deviation: 14.29

Mean Change in Nodule Areas, All Administrations of 6 Weeks Each (n=68), AI (n=39) Versus P (n=29)

Mean modification in the area of the nodules in cm^2, calculated as the difference between the initial and final nodule area after 6 weeks of administration of either AI (total 39 administrations) or P (total 29 administrations), and standard deviation

All AI Administrations (n=39)

0.611
cm^2 (Mean)
Standard Deviation: 0.933

All P Administrations (n=29)

0.178
cm^2 (Mean)
Standard Deviation: 0.515

Total

34
Participants

Age, Continuous

53.44
years (Mean)
Standard Deviation: 12.63

Surface of Thyroid Nodules

4.387
cm^2 (Mean)
Standard Deviation: 3.139

Age, Categorical

Race (NIH/OMB)

Sex: Female, Male

First Intervention Weeks 0-6 (V1-V2)

Sequence AI-P: Active Ingredient (Spirulina) Then Placebo

Sequence P-AI: Placebo Then Active Ingredient (Spirulina)

Sequence AI-AI (Active Ingredient, Then Active Ingredient)

Second Intervention Weeks 6-12 (V2-V3)

Sequence AI-P: Active Ingredient (Spirulina) Then Placebo

Sequence P-AI: Placebo Then Active Ingredient (Spirulina)

Sequence AI-AI (Active Ingredient, Then Active Ingredient)

Drop/Withdrawal Reasons

Sequence AI-P: Active Ingredient (Spirulina) Then Placebo

Sequence P-AI: Placebo Then Active Ingredient (Spirulina)